Home
Sessions
Evolving Paradigms in High-Risk Breast Cancer: Optimization and Integration of Treatment Modalities Across the Disease Continuum
Toxicity Results from TBCRC-053 (P-RAD): A Randomized Trial of No, Low or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive HER2-Negative Breast Cancer

Sep 29

SS 40 - Evolving Paradigms in High-Risk Breast Cancer: Optimization and Integration of Treatment Modalities Across the Disease Continuum

318 - Toxicity Results from TBCRC-053 (P-RAD): A Randomized Trial of No, Low or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive HER2-Negative Breast Cancer

03:55pm - 04:05pm ET

Presenter(s)

Elitza Koutleva, MD, MBA - University of North Carolina at Chapel Hill, Chapel Hill, NC